This document is an excerpt from the EUR-Lex website
Document 62016TA0088
Case T-88/16: Judgment of the General Court of 26 January 2017 — Opko Ireland Global Holdings v EUIPO — Teva Pharmaceutical Industries (ALPHAREN) (EU trade mark — Opposition proceedings — Application for EU word mark ALPHAREN — Earlier national word marks ALPHA D3 — Relative ground for refusal — Likelihood of confusion — Article 8(1)(b) of Regulation (EC) No 207/2009 — Consideration of new evidence by the Board of Appeal following a judgment annulling a decision — Article 76(2) of Regulation No 207/2009)
Case T-88/16: Judgment of the General Court of 26 January 2017 — Opko Ireland Global Holdings v EUIPO — Teva Pharmaceutical Industries (ALPHAREN) (EU trade mark — Opposition proceedings — Application for EU word mark ALPHAREN — Earlier national word marks ALPHA D3 — Relative ground for refusal — Likelihood of confusion — Article 8(1)(b) of Regulation (EC) No 207/2009 — Consideration of new evidence by the Board of Appeal following a judgment annulling a decision — Article 76(2) of Regulation No 207/2009)
Case T-88/16: Judgment of the General Court of 26 January 2017 — Opko Ireland Global Holdings v EUIPO — Teva Pharmaceutical Industries (ALPHAREN) (EU trade mark — Opposition proceedings — Application for EU word mark ALPHAREN — Earlier national word marks ALPHA D3 — Relative ground for refusal — Likelihood of confusion — Article 8(1)(b) of Regulation (EC) No 207/2009 — Consideration of new evidence by the Board of Appeal following a judgment annulling a decision — Article 76(2) of Regulation No 207/2009)
OJ C 78, 13.3.2017, p. 29–30
(BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
- Date of document:
- 26/01/2017
- Date lodged:
- 26/02/2016
- Author:
- General Court
- Form:
- Judicial information
- Authentic language:
- English
- Type of procedure:
- Action for annulment - unfounded
- Link
- Select all documents mentioning this document
- Case affecting:
-
- Related EU case-law document 62016TJ0088
- Instruments cited in case law:
- Link
- EUROVOC descriptor:
|
13.3.2017 |
EN |
Official Journal of the European Union |
C 78/29 |
Judgment of the General Court of 26 January 2017 — Opko Ireland Global Holdings v EUIPO — Teva Pharmaceutical Industries (ALPHAREN)
(Case T-88/16) (1)
((EU trade mark - Opposition proceedings - Application for EU word mark ALPHAREN - Earlier national word marks ALPHA D3 - Relative ground for refusal - Likelihood of confusion - Article 8(1)(b) of Regulation (EC) No 207/2009 - Consideration of new evidence by the Board of Appeal following a judgment annulling a decision - Article 76(2) of Regulation No 207/2009))
(2017/C 078/40)
Language of the case: English
Parties
Applicant: Opko Ireland Global Holdings Ltd (Dublin, Ireland) (represented by: S. Malynicz QC, A. Smith and D. Meale, Solicitors)
Defendant: European Union Intellectual Property Office (represented by: A. Folliard-Monguiral, acting as Agent)
Other party to the proceedings before the Board of Appeal of EUIPO: Teva Pharmaceutical Industries Ltd (Jerusalem, Israel)
Re:
Action brought against the decision of the Fifth Board of Appeal of EUIPO of 16 December 2015 (Case R 2387/2014-5), relating to opposition proceedings between Teva Pharmaceutical Industries and Opko Ireland Global Holdings.
Operative part of the judgment
The Court:
|
1. |
Dismisses the action; |
|
2. |
Orders Opko Ireland Global Holdings Ltd to pay the costs. |
